252 related articles for article (PubMed ID: 37925136)
1. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
[TBL] [Abstract][Full Text] [Related]
2. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
[TBL] [Abstract][Full Text] [Related]
3. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
4. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
5. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.
Videira NB; Nair V; Paquet V; Calhoun D
J Appl Toxicol; 2024 Feb; 44(2):216-234. PubMed ID: 37646119
[TBL] [Abstract][Full Text] [Related]
6. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
7. Psychedelic drugs-a new era in
psychiatry?
.
Nutt D
Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
[TBL] [Abstract][Full Text] [Related]
8. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ
Biomed Pharmacother; 2023 Dec; 169():115775. PubMed ID: 37944438
[TBL] [Abstract][Full Text] [Related]
9. Dosing Psychedelics and MDMA.
Liechti ME; Holze F
Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
[TBL] [Abstract][Full Text] [Related]
10. Psychedelic drugs for psychiatric disorders.
da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
[TBL] [Abstract][Full Text] [Related]
11. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
[TBL] [Abstract][Full Text] [Related]
12. The promises and perils of psychedelic pharmacology for psychiatry.
McClure-Begley TD; Roth BL
Nat Rev Drug Discov; 2022 Jun; 21(6):463-473. PubMed ID: 35301459
[TBL] [Abstract][Full Text] [Related]
13. The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics.
Hadar A; David J; Shalit N; Roseman L; Gross R; Sessa B; Lev-Ran S
J Psychoactive Drugs; 2023; 55(1):1-10. PubMed ID: 35000572
[TBL] [Abstract][Full Text] [Related]
14. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
Barnett BS; Parker SE; Weleff J
Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
[TBL] [Abstract][Full Text] [Related]
15. The use of classic psychedelics among adults: a Danish online survey study.
Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
[TBL] [Abstract][Full Text] [Related]
16. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
[No Abstract] [Full Text] [Related]
17. Analysis of recreational psychedelic substance use experiences classified by substance.
Hase A; Erdmann M; Limbach V; Hasler G
Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
[TBL] [Abstract][Full Text] [Related]
18. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
Ezeaka UC; Kim HJJ; Laprairie RB
Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
[TBL] [Abstract][Full Text] [Related]
19. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects.
Hosanagar A; Cusimano J; Radhakrishnan R
J Clin Psychiatry; 2021 Feb; 82(2):. PubMed ID: 33988926
[No Abstract] [Full Text] [Related]
[Next] [New Search]
